Men Undergoing Brachytherapy Alone for Aggressive Prostate Cancer May be Under-Treated

Boston, Massachusetts (PressExposure) August 11, 2009 -- In the first and only study designed to compare a single prostate cancer treatment, brachytherapy, to a combination of treatment methods for differences in mortality rates in men with high-risk prostate cancer, researchers at Brigham and Women's Hospital (BWH) have found that a single treatment method of brachytherapy, also called seed therapy, alone is associated with higher death rates from prostate cancer. This research is published online and in an upcoming print edition of the Journal of Clinical Oncology.

"Despite the increasing numbers of men worldwide who choose to undergo brachytherapy alone for their high-risk, prostate cancer, the evidence supporting this treatment method alone based on survival data from randomized trials is lacking" said Anthony D'Amico, MD, PhD, lead researcher and chief of genitourinary radiation oncology at BWH."In order to get the highest cure rate for men with high risk prostate cancer, it appears that five weeks of external beam radiation and at least four months of hormonal therapy should be added to brachytherapy."

To address the difference in mortality rates, researchers evaluated the difference in the risk of death from prostate cancer in 1,342 men with high-risk cancer and at least a 10-year life expectancy. Participants were treated at one of 21 community- based medical centers in the United States using brachytherapy alone or in conjunction with hormone therapy (androgen suppression therapy), external beam radiation therapy or both. High-risk cancer was defined as having cancer felt beyond the prostate capsule on exam or having a prostate-specific antigen level over 20 or Gleason score between eight and 10 inclusive.

The study disclosed that despite a higher baseline risk of death from prostate cancer, men who underwent a combination therapy of brachytherapy, hormone therapy and external beam radiation had a lower risk of death from prostate cancer after treatment when compared to men who brachytherapy alone or the combination of external beam radiation and had brachytheapy or hormonal therapy and brachytherapy.

About Brigham and Women's Hospital

Brigham and Women's Hospital (BWH) is a 777-bed nonprofit teaching affiliate of Harvard Medical School and a founding member of Partners HealthCare, an integrated health care delivery system. BWH is committed to excellence in patient care with expertise in virtually every specialty of medicine and surgery. The BWH medical preeminence dates back to 1832, and today that rich history in clinical care is coupled with its national leadership in quality improvement and patient safety initiatives and its dedication to educating and training the next generation of health care professionals. In July 2008, the hospital opened the Carl J. and Ruth Shapiro Cardiovascular Center, the most advanced center of its kind. Through investigation and discovery conducted at its Biomedical Research Institute (BRI), BWH is an international leader in basic, clinical and translational research on a diversity of human diseases and is at the forefront of personalized medicine. BWH has approximately 900 scientific investigators and more than $450 million in research support, more than 50 percent of which comes from the NIH. BWH is also home to major landmark population studies, including the Nurses' and Physicians' Health Studies and the Women's Health Initiative, which have provided important information on diet and lifestyle risk factors for common chronic diseases. For more information about BWH, please visit Brigham and Women's Hospital.

Press Release Source:'s_Hospital.html

Press Release Submitted On: August 10, 2009 at 7:46 am
This article has been viewed 30356 time(s).